Status:

COMPLETED

Phase III Study of Topical Gel for Treatment and Prevention of Raynaud's Phenomenon

Lead Sponsor:

MediQuest Therapeutics

Conditions:

Raynaud's Disease

Eligibility:

All Genders

18-70 years

Phase:

PHASE3

Brief Summary

The purpose of this study is to investigate the efficacy and safety of a topical gel formulation of nitroglycerin, in comparison to a matching placebo, for patients with moderate to severe primary Ray...

Eligibility Criteria

Inclusion

  • Clinical diagnosis of Raynaud's phenomenon
  • 2 or more Raynaud's events on a typical winter day
  • Agree to discontinue current treatments for Raynaud's
  • Negative pregnancy test and agree to use effective contraception during study

Exclusion

  • Current use of nitrate medications or medications known to interact with nitroglycerin
  • Patients who currently use medications, like calcium channel blockers, that might interfere with study medication
  • Patients with a known allergy to nitroglycerin or common topical ingredients
  • Patients with a history of migraine headaches
  • Patients with a history of unstable medical problems
  • Patients with cognitive or language difficulties that would impair completion of assessment instruments
  • Patients with lab screening values more than 20% outside normal range
  • Patients with non-epithelialized skin lesions, in the area where the gel is to be applied, at the time of screening
  • Pregnant or nursing women
  • Women of child-bearing potential who are unwilling to comply with the contraceptive requirements

Key Trial Info

Start Date :

December 1 2005

Trial Type :

INTERVENTIONAL

End Date :

May 1 2006

Estimated Enrollment :

200 Patients enrolled

Trial Details

Trial ID

NCT00266669

Start Date

December 1 2005

End Date

May 1 2006

Last Update

August 8 2007

Active Locations (19)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 5 (19 locations)

1

Stanford Medical School

Stanford, California, United States, 94305

2

University of Colorado at Denver and Health Sciences Center

Denver, Colorado, United States, 80204

3

University of Connecticut

Farmington, Connecticut, United States, 06030

4

Georgetown University Medical Center

Washington D.C., District of Columbia, United States, 20007

Phase III Study of Topical Gel for Treatment and Prevention of Raynaud's Phenomenon | DecenTrialz